

International Conference and Expo on

Generic Drug Market & Contract Manufacturing

November 07-09, 2016 Barcelona, Spain

The future of quality generic pharmaceutical manufacturing in Asia: A clash of cultures?

Alan Liss

GXP Farma, LLC—Consulting, USA

Global pharmaceutical trends confirm the importance of Asian pharmaceutical manufacturing facilities as the most critical aspect of maintaining the supply of many of the drugs currently on the market. However, recurring issues in regard to product quality and general compliance to established quality standards put a potential cloud over the otherwise bright future of this region of the pharma world. This presentation shall summarize information gained while a member of US FDA and as a current subject matter expert in Asia regarding current, present and future compliance to regulatory standards in key Asian markets. Data emphasis will be on small molecule generics but with a critical evaluation of the future of biosimilars produced in these same areas. The connection between pharmaceutical standards and cultural norms will be made and how these will affect the future of manufacturing in Asia, specifically and the global pharmaceutical supply chain in general.

lissnest@yahoo.com

European generic pharmaceuticals market: The potential saving in many European countries are not completely exploited

Unmesh Lal

Frost & Sullivan, USA

Europe is one of the world's largest generic pharmaceuticals market accounting for 16.4% of the global sales valued at \$54.32 billion in 2015. The generics market is expected to grow at a moderate CAGR (2015-2020) of 7.4% to reach \$77.72 billion by 2020. Generics constitute almost 55% of dispensed medicine and 21% of pharmaceutical expenditure. Frost & Sullivan has recently completed a comprehensive analysis on the global generic market. The key objectives of this research are to gain an in-depth knowledge of the major markets, therapeutic areas and organizations presenting significant growth opportunities for generics, to understand the impact of regulation on the market and to outline the industry consolidation trends which will continue shaping the future of generics. Through our research, we were able to understand current economic conditions and forecast future revenues for the generic pharmaceuticals market, both globally and regionally. It would enable the market participants to take strategic decisions in order to stay ahead of their competitors and gain significant share in the market. The aim of this presentation is to analyze the EU generic pharmaceuticals market (Germany, UK, France, Spain & Italy) with regard to the revenue prospects of developed as well as emerging economies, map the key trends and dynamics shaping the industry sector and provide strategic recommendations and conclusions for the success of the market participants. The robust analysis covers the impact of changing trends such as implementation of differentiating business models for established generics market, newer generics and biosimilars ecosystem, impact of premium pricing portfolio, etc. The presentation will also throw light on how several generic companies are transforming themselves from low margin formulation to high margin formulation manufacturers in order to beat the competition. Additional highlights of the presentation shall include: Top attractive segments; revenue forecasts; key trends & market opportunities; companies to watch; and different market models.

UnmeshL@frost.com